Company intelligence / Profile preview

Mucokinetica

United Kingdom

Ownership: Private
Development stage: Other

Overview

Mucokinetica's main program is focused on inhaled nafamostat for enhancing mucociliary clearance, with pre-clinical and early-stage data suggesting promising efficacy in clearing infected, purulent secretions in respiratory disease models and as a potent inhibitor of SARS-CoV-2 infection in respiratory epithelial cells[2].

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Mucokinetica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucokinetica.

Explore the full profile